The Role of Cancer-Associated Fibroblasts and Fibrosisin Liver Cancer

Annual Review of Pathology: Mechanisms of Disease

Volumn 12, Issue , 2017, Pages 153-186

  Affo, Silvia ^a   Yu, Le Xing ^a   Schwabe, Robert F ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Fluke; Inflammation; Mechanosensitive signaling; Primary sclerosing cholangitis (PSC); Stiffness; Stroma

Indexed keywords

CYTOKINE; GROWTH FACTOR;

ANGIOGENESIS; BILE DUCT CARCINOMA; CANCER ASSOCIATED FIBROBLAST; CANCER GROWTH; CANCER SURVIVAL; CELL AGING; CELL DEATH; CELL PROLIFERATION; EXTRACELLULAR MATRIX; HEPATIC STELLATE CELL; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INFLAMMATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; MECHANOTRANSDUCTION; MYELOID-DERIVED SUPPRESSOR CELL; MYOFIBROBLAST; NONHUMAN; PRECANCER; PRIORITY JOURNAL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; LIVER CIRRHOSIS; LIVER TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CANCER-ASSOCIATED FIBROBLASTS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MYOFIBROBLASTS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 85011281125     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-052016-100322     Document Type: Review

References (265)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. 2015. Global cancer statistics, 2012. CA Cancer J. Clin. 65:87-108
2. Nault JC, Bioulac-Sage P, Zucman-Rossi J. 2013. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 144:888-902
3. Ladep NG, Khan SA, Crossey MM, Thillainayagam AV, Taylor-Robinson SD, Toledano MB. 2014. Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations. World J. Gastroenterol. 20:1544-53
4. Taylor-Robinson SD,Toledano MB, Arora S,Keegan TJ,Hargreaves S, et al. 2001. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 48:816-20
5. West J, Wood H, Logan RF, Quinn M, Aithal GP. 2006. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br. J. Cancer 94:1751-58
6. El-Serag HB. 2011. Hepatocellular carcinoma. N. Engl. J. Med. 365:1118-27
7. Rizvi S, Gores GJ. 2013. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145:1215-29
8. Hanahan D, Coussens LM. 2012. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309-22
9. Hanahan D,Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-74
10. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, et al. 2008. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359:1995-2004
11. Sirica AE. 2012. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 9:44-54
12. Baffy G, Brunt EM, Caldwell SH. 2012. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J. Hepatol. 56:1384-91
13. Singal AG, El-Serag HB. 2015. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin. Gastroenterol. Hepatol. 13:2140-51
14. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. 2013. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: ameta-analysis of observational studies. Ann. Intern. Med. 158:329-37
15. Di Marco V, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, et al. 2016. Effects of viral eradication in patients with HCV and cirrhosis differ with stage of portal hypertension. Gastroenterology 151:130-139.e2
16. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. 2015. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149:1226-1239.e4
17. Mu X, Espanol-Suner R, Mederacke I, Affo S,Manco R, et al. 2015. Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment. J. Clin. Investig. 125:3891-903
18. Hernandez-Gea V, Friedman SL. 2011. Pathogenesis of liver fibrosis. Annu. Rev. Pathol. 6:425-56
19. Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. 2013. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144:512-27
20. Bissell MJ, Hines WC. 2011. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 17:320-29
21. Farazi PA,DePinho RA. 2006. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6:674-87
22. Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, et al. 2016. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature 531:253-57
23. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. 2005. IKKβcouples hepatocyte death to cytokinedriven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121:977-90
24. Zhang XF, Tan X, Zeng G, Misse A, Singh S, et al. 2010. Conditional β-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor α/phosphoinositide 3-kinase signaling. Hepatology 52:954-65
25. Seki E, Schwabe RF. 2015. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology 61:1066-79
26. O'Brien AJ, Fullerton JN, Massey KA, Auld G, Sewell G, et al. 2014. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat. Med. 20:518-23
27. Caviglia JM, Schwabe RF. 2015. Mouse models of liver cancer. Methods Mol. Biol. 1267:165-83
28. Luedde T, Kaplowitz N, Schwabe RF. 2014. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 147:765-783.e4
29. Takehara T, Tatsumi T, Suzuki T, Rucker EB, Hennighausen L, et al. 2004. Hepatocyte-specific disruption ofBcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 127:1189-97
30. Vick B, Weber A, Urbanik T, Maass T, Teufel A, et al. 2009. Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology 49:627-36
31. Weber A, Boger R, Vick B, Urbanik T, Haybaeck J, et al. 2010. Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology 51:1226-36
32. Hikita H, Kodama T, Shimizu S, Li W, Shigekawa M, et al. 2012. Bak deficiency inhibits liver carcinogenesis: a causal link between apoptosis and carcinogenesis. J. Hepatol. 57:92-100
33. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, et al. 2007. Deletion of NEMO/IKKγin liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11:119-32
34. Chen CF, Lee WC, YangHI, ChangHC, JenCL, et al. 2011. Changes in serum levels ofHBVDNAand alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 141:1240-1248.e2
35. Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, et al. 2010. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J. Clin. Oncol. 28:4587-93
36. Liu X, He Y, Li F, Huang Q, Kato TA, et al. 2015. Caspase-3 promotes genetic instability and carcinogenesis. Mol. Cell 58:284-96
37. Ichim G, Lopez J, Ahmed SU, Muthalagu N, Giampazolias E, et al. 2015. Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol. Cell 57:860-72
38. Rojkind M, Giambrone MA, Biempica L. 1979. Collagen types in normal and cirrhotic liver. Gastroenterology 76:710-19
39. Friedman SL. 2015. Extracellular matrix. In Signaling Pathways in Liver Diseases, ed. J-F Dufour, P-A Clavien, pp. 85-96. Chichester, UK:Wiley
40. Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, et al. 2013. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat.Med. 19:1617-24
41. Olaso E, Ikeda K, Eng FJ, Xu L, Wang LH, et al. 2001. DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J. Clin. Investig. 108:1369-78
42. Walsh LA, Nawshad A,Medici D. 2011. Discoidin domain receptor 2 is a critical regulator of epithelialmesenchymal transition. Matrix Biol. 30:243-47
43. ZhangK,Corsa CA, Ponik SM, Prior JL, Piwnica-WormsD, et al. 2013. The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nat. Cell Biol. 15:677-87
44. Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, et al. 2013. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat. Commun. 4:2823
45. Friedman SL. 2008. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 88:125-72
46. Suh B, Park S, Shin DW, Yun JM, Yang HK, et al. 2015. High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. Hepatology 61:1261-68
47. Kim MN, Kim SU, Kim BK, Park JY, Kim do Y, et al. 2015. Increased risk of hepatocellular carcinoma in chronic hepatitisBpatientswith transient elastography-defined subclinical cirrhosis. Hepatology 61:1851-59
48. Akima T, TamanoM,Hiraishi H. 2011. Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis. Hepatol. Res. 41:965-70
49. Wang HM, Hung CH, Lu SN, Chen CH, Lee CM, et al. 2013. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients. Liver Int. 33:756-61
50. Zhang DY, Goossens N, Guo J, Tsai MC, Chou HI, et al. 2016. A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut 65:1754-64
51. Wang Q, Fiel MI, Blank S, LuanW, Kadri H, et al. 2013. Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. Br. J. Cancer 109:573-81
52. Ju MJ,Qiu SJ, Fan J, Xiao YS,Gao Q, et al. 2009. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am. J. Clin. Pathol. 131:498-510
53. Ji J, Eggert T, Budhu A, Forgues M, Takai A, et al. 2015. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. Hepatology 62:481-95
54. Czauderna P,Mackinlay G, Perilongo G, Brown J, Shafford E, et al. 2002. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J. Clin. Oncol. 20:2798-804
55. Yang JD, Kim WR, Coelho R,Mettler TA, Benson JT, et al. 2011. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 9:64-70
56. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, et al. 2013. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed. Res. Int. 2013:187204
57. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, et al. 2009. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16:295-308
58. Wilson CL, Jurk D, Fullard N, Banks P, Page A, et al. 2015. NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma. Nat. Commun. 6:6818
59. Moles A, Murphy L, Wilson CL, Chakraborty JB, Fox C, et al. 2014. A TLR2/S100A9/CXCL-2 signaling network is necessary for neutrophil recruitment in acute and chronic liver injury in the mouse. J. Hepatol. 60:782-91
60. Saito JM, Bostick MK, Campe CB, Xu J, Maher JJ. 2003. Infiltrating neutrophils in bile duct-ligated livers do not promote hepatic fibrosis. Hepatol. Res. 25:180-91
61. Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, et al. 2015. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat. Immunol. 16:1235-44
62. He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, et al. 2013. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 155:384-96
63. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, et al. 2007. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317:121-24
64. Kovalovich K, DeAngelis RA, Li W, Furth EE, Ciliberto G, Taub R. 2000. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology 31:149-59
65. Streetz KL, Wustefeld T, Klein C, Kallen KJ, Tronche F, et al. 2003. Lack of gp130 expression in hepatocytes promotes liver injury. Gastroenterology 125:532-43
66. Pradere JP, Kluwe J, de Minicis S, Jiao JJ, Gwak GY, et al. 2013. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology 58:1461-73
67. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, et al. 2010. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1βin mice. Gastroenterology 139:323-334.e7
68. Sakurai T, He G,Matsuzawa A, Yu GY, Maeda S, et al. 2008. Hepatocyte necrosis induced by oxidative stress and IL-1αreleasemediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14:156-65
69. Seki E, de Minicis S, Osterreicher CH, Kluwe J, Osawa Y, et al. 2007. TLR4 enhances TGF-βsignaling and hepatic fibrosis. Nat. Med. 13:1324-32
70. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, et al. 2012. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21:504-16
71. Schreiber RD, Old LJ, SmythMJ. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:1565-70
72. Sharma P, Allison JP. 2015. The future of immune checkpoint therapy. Science 348:56-61
73. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, et al. 2011. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479:547-51
74. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. 2010. The polarization of immune cells in the tumour environment by TGF and beta;. Nat. Rev. Immunol. 10:554-67
75. Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, et al. 2013. Non-cell-autonomous tumor suppression by p53. Cell 153:449-60
76. Lai KK, Shang S, Lohia N, Booth GC, Masse DJ, et al. 2011. Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLOS Genet. 7:e1002147
77. Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, et al. 2013. Mechanotransduction and YAPdependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat. Cell Biol. 15:637-46
78. Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP. 2009. Unique phenotype of hepatocellular cancers with exon-3 mutations in β-catenin gene. Hepatology 49:821-31
79. Dal Bello B, Rosa L, Campanini N, Tinelli C, Torello Viera F, et al. 2010. Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation. Clin. Cancer Res. 16:2157-66
80. Coulouarn C, Corlu A,GlaiseD,Guenon I, Thorgeirsson SS, Clement B. 2012. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res. 72:2533-42
81. Lau EY, Lo J, Cheng BY, Ma MK, Lee JM, et al. 2016. Cancer-associated fibroblasts regulate tumorinitiating cell plasticity in hepatocellular carcinoma through c-Met/FRA1/HEY1 signaling. Cell Rep. 15:1175-89
82. Mikula M, Proell V, Fischer AN, Mikulits W. 2006. Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF-βdependent fashion. J. Cell Physiol. 209:560-67
83. Amann T, Bataille F, Spruss T, Muhlbauer M, Gabele E, et al. 2009. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci. 100:646-53
84. ZhaoW,ZhangL,Yin Z, SuW,RenG, et al. 2011. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int. J. Cancer 129:2651-61
85. Wang ZM, Zhou LY, Liu BB, Jia QA, Dong YY, et al. 2014. Rat hepatic stellate cells alter the gene expression profile and promote the growth, migration and invasion of hepatocellular carcinoma cells. Mol. Med. Rep. 10:1725-33
86. Zhu AX, Duda DG, Sahani DV, Jain RK. 2011. HCC and angiogenesis: possible targets and future directions. Nat. Rev. Clin. Oncol. 8:292-301
87. van Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, et al. 2010. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141:178-90
88. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, et al. 2002. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 35:834-42
89. Ding BS, Cao Z, Lis R, Nolan DJ, Guo P, et al. 2014. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature 505:97-102
90. Lin N, Chen Z, Lu Y, Li Y, Hu K, Xu R. 2015. Role of activated hepatic stellate cells in proliferation and metastasis of hepatocellular carcinoma. Hepatol. Res. 45:326-36
91. TauraK, Minicis S, Seki E, Hatano E, IwaisakoK, et al. 2008. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 135:1729-38
92. Gordon S, Taylor PR. 2005. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5:953-64
93. Condeelis J, Pollard JW. 2006. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124:263-66
94. Noy R, Pollard JW. 2014. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41:49-61
95. Qian BZ, Pollard JW. 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141:39-51
96. ZhuXD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, et al. 2008. High expression of macrophage colonystimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J. Clin. Oncol. 26:2707-16
97. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, et al. 2009. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206:1327-37
98. Ding T, Xu J, Wang F, Shi M, Zhang Y, et al. 2009. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum. Pathol. 40:381-89
99. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, et al. 2005. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Investig. 115:56-65
100. Ide M, Kuwamura M, Kotani T, Sawamoto O, Yamate J. 2005. Effects of gadolinium chloride (GdCl3) on the appearance of macrophage populations and fibrogenesis in thioacetamide-induced rat hepatic lesions. J. Comp. Pathol. 133:92-102
101. Li H, Wu K, Tao K, Chen L, Zheng Q, et al. 2012. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patientswith hepatitis B virus-associated hepatocellular carcinoma. Hepatology 56:1342-51
102. Wan S, Kuo N, Kryczek I, Zou W, Welling TH. 2015. Myeloid cells in hepatocellular carcinoma. Hepatology 62:1304-12
103. Kapanadze T, Gamrekelashvili J, Ma C, Chan C, Zhao F, et al. 2013. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J. Hepatol. 59:1007-13
104. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, et al. 2008. A new population of myeloidderived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells. Gastroenterology 135:234-43
105. Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y. 2013. Higher frequencies of GARP+CTLA-4+Foxp3+ T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 73:2435-44
106. Hochst B, Schildberg FA, Sauerborn P, Gabel YA, Gevensleben H, et al. 2013. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion. J. Hepatol. 59:528-35
107. Zhao W, Zhang L, Xu Y, Zhang Z, Ren G, et al. 2014. Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model. Lab. Investig. 94:182-91
108. Resheq YJ, Li KK, Ward ST,Wilhelm A,Garg A, et al. 2015. Contact-dependent depletion of hydrogen peroxide by catalase is a novel mechanism of myeloid-derived suppressor cell induction operating in human hepatic stellate cells. J. Immunol. 194:2578-86
109. Xu Y, Zhao W, Xu J, Li J, Hong Z, et al. 2016. Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2. Oncotarget 7:8866-78
110. Arihara F, Mizukoshi E, Kitahara M, Takata Y, Arai K, et al. 2013. Increase in CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol. Immunother. 62:1421-30
111. Hynes RO. 2009. The extracellular matrix: not just pretty fibrils. Science 326:1216-19
112. Rombouts K, Carloni V. 2013. The fibrotic microenvironment as a heterogeneity facet of hepatocellular carcinoma. Fibrogenes. Tissue Repair 6:17
113. Carloni V, LuongTV, RomboutsK. 2014. Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. Liver Int. 34:834-43
114. Santamato A, Fransvea E, Dituri F, Caligiuri A, Quaranta M, et al. 2011. Hepatic stellate cells stimulate HCC cell migration via laminin-5 production. Clin. Sci. 121:159-68
115. Gkretsi V, Mars WM, Bowen WC, Barua L, Yang Y, et al. 2007. Loss of integrin linked kinase from mouse hepatocytes in vitro and in vivo results in apoptosis and hepatitis. Hepatology 45:1025-34
116. Begum NA, Mori M, Matsumata T, Takenaka K, Sugimachi K, Barnard GF. 1995. Differential display and integrin α6 messenger RNA overexpression in hepatocellular carcinoma. Hepatology 22:1447-55
117. Zhao G, Cui J, Qin Q, Zhang J, Liu L, et al. 2010. Mechanical stiffness of liver tissues in relation to integrinβ1 expression may influence the development of hepatic cirrhosis and hepatocellular carcinoma. J. Surg. Oncol. 102:482-89
118. Lee SK, Kim MH,Cheong JY, Cho SW, Yang SJ,Kwack K. 2009. IntegrinαV polymorphisms and haplotypes in a Korean population are associated with susceptibility to chronic hepatitis and hepatocellular carcinoma. Liver Int. 29:187-95
119. Cox D, Brennan M, Moran N. 2010. Integrins as therapeutic targets: lessons and opportunities. Nat. Rev. Drug Discov. 9:804-20
120. Zhang DY, Friedman SL. 2012. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 56:769-75
121. Shrivastava A, Radziejewski C, Campbell E, Kovac L, McGlynn M, et al. 1997. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol. Cell 1:25-34
122. Xie B, Lin W, Ye J, Wang X, Zhang B, et al. 2015. DDR2 facilitates hepatocellular carcinoma invasion and metastasis via activating ERK signaling and stabilizing SNAIL1. J. Exp. Clin. Cancer Res. 34:101
123. Park JW, Lee YS, Kim JS, Lee SK, Kim BH, et al. 2015. Downregulation of discoidin domain receptor 2 decreases tumor growth of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 141:1973-83
124. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, et al. 2009. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139:891-906
125. Lu P, Weaver VM, Werb Z. 2012. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 196:395-406
126. Samuel MS, Lopez JI, McGhee EJ, Croft DR, Strachan D, et al. 2011. Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell 19:776-91
127. Laklai H, Miroshnikova YA, PickupMW,Collisson EA, Kim GE, et al. 2016. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat. Med. 22:497-505
128. Naba A, Clauser KR, Lamar JM, Carr SA, Hynes RO. 2014. Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. eLife 3:e01308
129. Fernandez-SanchezME, Barbier S,Whitehead J, Bealle G, Michel A, et al. 2015. Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressure. Nature 523:92-95
130. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, et al. 2005. Tensional homeostasis and the malignant phenotype. Cancer Cell 8:241-54
131. Schrader J, Gordon-Walker TT, Aucott RL, van Deemter M, Quaas A, et al. 2011. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology 53:1192-205
132. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, et al. 2011. Role of YAP/TAZ in mechanotransduction. Nature 474:179-83
133. MouwJK,Yui Y, DamianoL,Bainer RO,Lakins JN, et al. 2014. Tissuemechanics modulatemicroRNAdependent PTEN expression to regulate malignant progression. Nat. Med. 20:360-67
134. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, et al. 2010. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. PNAS 107:1437-42
135. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, et al. 2004. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Investig. 113:1774-83
136. Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, et al. 2009. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis Cby transient elastography. Hepatology 49:1954-61
137. Williams MJ, Clouston AD, Forbes SJ. 2014. Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. Gastroenterology 146:349-56
138. Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, et al. 2002. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int. J. Cancer 97:425-31
139. Okazaki I. 2012. Novel cancer-targeting agents/application strategies developed from MMP science. Anticancer Agents Med. Chem. 12:687
140. Jia YL, Shi L, Zhou JN, Fu CJ, Chen L, et al. 2011. Epimorphin promotes human hepatocellular carcinoma invasion and metastasis through activation of focal adhesion kinase/extracellular signal-regulated kinase/matrix metalloproteinase-9 axis. Hepatology 54:1808-18
141. Zhao W, Su W, Kuang P, Zhang L, Liu J, et al. 2012. The role of hepatic stellate cells in the regulation of T-cell function and the promotion of hepatocellular carcinoma. Int. J. Oncol. 41:457-64
142. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, et al. 2009. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via theNKp30 receptor. Hepatology 50:799-807
143. Kang N, Gores GJ, Shah VH. 2011. Hepatic stellate cells: partners in crime for liver metastases? Hepatology 54:707-13
144. Rosmorduc O, Housset C. 2010. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin. Liver Dis. 30:258-70
145. Ankoma-Sey V, Wang Y, Dai Z. 2000. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 31:141-48
146. Sanz-Cameno P,Martin-Vilchez S, Lara-Pezzi E, Borque MJ, Salmeron J, et al. 2006. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV X protein. Am. J. Pathol. 169:1215-22
147. Torimura T, Ueno T, Kin M, Harada R, Taniguchi E, et al. 2004. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J. Hepatol. 40:799-807
148. Geng ZM, Li QH, Li WZ, Zheng JB, Shah V. 2014. Activated human hepatic stellate cells promote growth of human hepatocellular carcinoma in a subcutaneous xenograft nude mousemodel. Cell Biochem. Biophys. 70:337-47
149. Olaso E, Salado C, Egilegor E, Gutierrez V, Santisteban A, et al. 2003. Proangiogenic role of tumoractivated hepatic stellate cells in experimental melanoma metastasis. Hepatology 37:674-85
150. Kang N, Yaqoob U, Geng Z, Bloch K, Liu C, et al. 2010. Focal adhesion assembly in myofibroblasts fosters a microenvironment that promotes tumor growth. Am. J. Pathol. 177:1888-900
151. Chen JA, Shi M, Li JQ, Qian CN. 2010. Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. Hepatol. Int. 4:537-47
152. Zhang ZL, Liu ZS, Sun Q. 2006. Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J. Gastroenterol. 12:4241-45
153. Wirz W, Antoine M, Tag CG, Gressner AM, Korff T, et al. 2008. Hepatic stellate cells display a functional vascular smooth muscle cell phenotype in a three-dimensional co-culture model with endothelial cells. Differentiation 76:784-94
154. Shimizu S, Yamada N, Sawada T, Ikeda K, Kawada N, et al. 2000. In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells. Jpn. J. Cancer Res. 91:1285-95
155. Song J, Ge Z, Yang X, Luo Q, Wang C, et al. 2015. Hepatic stellate cells activated by acidic tumor microenvironment promote the metastasis of hepatocellular carcinoma via osteopontin. Cancer Lett. 356:713-20
156. Meindl-Beinker NM, Matsuzaki K, Dooley S. 2012. TGF-β signaling in onset and progression of hepatocellular carcinoma. Dig. Dis. 30:514-23
157. Stover DG, Bierie B, Moses HL. 2007. A delicate balance: TGF-β and the tumor microenvironment. J. Cell. Biochem. 101:851-61
158. Toyoda H, Komurasaki T, Uchida D, Takayama Y, Isobe T, et al. 1995. Epiregulin: a novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J. Biol. Chem. 270:7495-500
159. Ljubimova JY, Petrovic LM, Wilson SE, Geller SA, Demetriou AA. 1997. Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. J. Histochem. Cytochem. 45:79-87
160. Neaud V, Faouzi S, Guirouilh J, Le Bail B, Balabaud C, et al. 1997. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology 26:1458-66
161. Goyal L, MuzumdarMD, Zhu AX. 2013. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin. Cancer Res. 19:2310-18
162. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. 2006. Metregulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Investig. 116:1582-95
163. Zhao M, He HW, Sun HX, Ren KH, Shao RG. 2009. Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells. Biochem. Biophys. Res. Commun. 387:239-44
164. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, et al. 2013. Obesity-induced gutmicrobial metabolite promotes liver cancer through senescence secretome. Nature 499:97-101
165. SiaD,Tovar V, Moeini A, Llovet JM. 2013. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene 32:4861-70
166. Blechacz B, Komuta M, Roskams T, Gores GJ. 2011. Clinical diagnosis and staging of cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 8:512-22
167. Everhart JE, Ruhl CE. 2009. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology 136:1134-44
168. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, et al. 2016. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat. Rev. Gastroenterol. Hepatol. 13:261-80
169. Patel T. 2002. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2:10
170. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. 2006. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra-and extrahepatic cholangiocarcinoma in the United States. J. Natl. Cancer Inst. 98:873-75
171. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J. Clin. 61:69-90
172. Shin HR, Oh JK, Lim MK, Shin A, Kong HJ, et al. 2010. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J. Korean Med. Sci. 25:1011-16
173. Shin HR, Oh JK,Masuyer E, Curado MP, Bouvard V, et al. 2010. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 101:579-85
174. Tyson GL, El-Serag HB. 2011. Risk factors for cholangiocarcinoma. Hepatology 54:173-84
175. Modha K, Navaneethan U. 2015. Diagnosis and management of primary sclerosing cholangitis-perspectives from a therapeutic endoscopist. World J. Hepatol. 7:799-805
176. Razumilava N, Gores GJ. 2014. Cholangiocarcinoma. Lancet 383:2168-79
177. Guest RV, Boulter L, Kendall TJ, Minnis-Lyons SE, Walker R, et al. 2014. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. Cancer Res. 74:1005-10
178. Mu X, Pradere JP, Affo S, Dapito DH, Friedman R, et al. 2016. Epithelial transforming growth factor-β signaling does not contribute to liver fibrosis but protects mice from cholangiocarcinoma. Gastroenterology 150:720-33
179. Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, et al. 2012. Cholangiocarcinomas can originate from hepatocytes in mice. J. Clin. Investig. 122:2911-15
180. Sekiya S, Suzuki A. 2012. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J. Clin. Investig. 122:3914-18
181. Yanger K, Zong Y, Maggs LR, Shapira SN, Maddipati R, et al. 2013. Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev. 27:719-24
182. Tarlow BD, Pelz C, Naugler WE,Wakefield L,Wilson EM, et al. 2014. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. Cell Stem Cell 15:605-18
183. Chan-On W, Nairismagi ML, Ong CK, Lim WK, Dima S, et al. 2013. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat. Genet. 45:1474-78
184. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, et al. 2013. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 45:1470-73
185. Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, et al. 2015. Genomic spectra of biliary tract cancer. Nat. Genet. 47:1003-10
186. Ong CK, Subimerb C, Pairojkul C,Wongkham S, Cutcutache I, et al. 2012. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat. Genet. 44:690-93
187. Sirica AE, Gores GJ. 2014. Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology 59:2397-402
188. Kim HJ, Kim JS, Suh SJ, Lee BJ, Park JJ, et al. 2015. Cholangiocarcinoma risk as long-term outcome after hepatic resection in the hepatolithiasis patients. World J. Surg. 39:1537-42
189. Kajiyama K, Maeda T, Takenaka K, Sugimachi K, Tsuneyoshi M. 1999. The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma: a special reference of 'scirrhous-type' and 'nonscirrhous-type' growth. Am. J. Surg. Pathol. 23:892-902
190. Mertens JC, Fingas CD, Christensen JD, Smoot RL, Bronk SF, et al. 2013. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 73:897-907
191. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X,Wu CC, et al. 2014. Depletion of carcinomaassociated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25:719-34
192. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, et al. 2014. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25:735-47
193. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, et al. 2013. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144:829-40
194. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. 2013. Primary sclerosing cholangitis. Lancet 382:1587-99
195. Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, et al. 2007. Liver fluke induces cholangiocarcinoma. PLOS Med. 4:e201
196. Qian MB, Utzinger J, Keiser J, Zhou XN. 2016. Clonorchiasis. Lancet 387:800-10
197. Sithithaworn P, Yongvanit P, Duenngai K, Kiatsopit N, Pairojkul C. 2014. Roles of liver fluke infection as risk factor for cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 21:301-8
198. Sripa B, Thinkhamrop B, Mairiang E, Laha T, Kaewkes S, et al. 2012. Elevated plasma IL-6 associates with increased risk of advanced fibrosis and cholangiocarcinoma in individuals infected by Opisthorchis viverrini. PLOS Negl. Trop. Dis. 6:e1654
199. Togo S, Polanska UM, Horimoto Y, Orimo A. 2013. Carcinoma-associated fibroblasts are a promising therapeutic target. Cancers 5:149-69
200. Chuaysri C, Thuwajit P, Paupairoj A, Chau-In S, Suthiphongchai T, Thuwajit C. 2009. And alpha-Smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol. Rep. 21:957-69
201. Okabe H, Beppu T, Hayashi H, Horino K, Masuda T, et al. 2009. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 16:2555-64
202. Utispan K, Thuwajit P, Abiko Y, Charngkaew K, Paupairoj A, et al. 2010. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol. Cancer 9:13
203. Leyva-Illades D, McMillin M, Quinn M, Demorrow S. 2012. Cholangiocarcinoma pathogenesis: role of the tumor microenvironment. Transl. Gastrointest. Cancer 1:71-80
204. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, et al. 2009. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mousemodel of pancreatic cancer. Science 324:1457-61
205. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. 2012. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21:418-29
206. Brivio S, CadamuroM, FabrisL, Strazzabosco M. 2015. Epithelial-to-mesenchymal transition and cancer invasiveness: What can we learn from cholangiocarcinoma? J. Clin. Med. 4:2028-41
207. Cadamuro M, Nardo G, Indraccolo S, Dall'olmo L, Sambado L, et al. 2013. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology 58:1042-53
208. Hu Q, Tong S, Zhao X, Ding W, Gou Y, et al. 2015. Periostin mediates TGF-β-induced epithelial mesenchymal transition in prostate cancer cells. Cell Physiol. Biochem. 36:799-809
209. Kyutoku M, Taniyama Y, Katsuragi N, Shimizu H, Kunugiza Y, et al. 2011. Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. Int. J. Mol. Med. 28:181-86
210. Morra L,Moch H. 2011. Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows. Arch. 459:465-75
211. Campbell DJ, Dumur CI, Lamour NF, Dewitt JL, Sirica AE. 2012. Novel organotypic culture model of cholangiocarcinoma progression. Hepatol. Res. 42:1119-30
212. Dumur CI, Campbell DJ, DeWitt JL, Oyesanya RA, Sirica AE. 2010. Differential gene expression profiling of cultured neu-transformed versus spontaneously-transformed rat cholangiocytes and of corresponding cholangiocarcinomas. Exp. Mol. Pathol. 89:227-35
213. Midwood KS,Orend G. 2009. The role of tenascin-C in tissue injury and tumorigenesis. J. Cell Commun. Signal. 3:287-310
214. Yoshida T, Akatsuka T, Imanaka-Yoshida K. 2015. Tenascin-C and integrins in cancer. Cell Adh. Migr. 9:96-104
215. Aishima S, Taguchi K, Terashi T, Matsuura S, Shimada M, Tsuneyoshi M. 2003. Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma. Mod. Pathol. 16:1019-27
216. Prakobwong S, Yongvanit P, Hiraku Y, Pairojkul C, Sithithaworn P, et al. 2010. Involvement of MMP-9 in peribiliary fibrosis and cholangiocarcinogenesis viaRac1-dependentDNAdamage in a hamster model. Int. J. Cancer 127:2576-87
217. Sirica AE, DumurCI, Campbell DJ, Almenara JA, Ogunwobi OO, Dewitt JL. 2009. Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clin. Gastroenterol. Hepatol. 7:S68-78
218. Terada T, Okada Y, Nakanuma Y. 1996. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 23:1341-44
219. Ling H, Roux E, Hempel D, Tao J, Smith M, et al. 2013. Transforming growth factor βneutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. PLOS ONE 8:e54499
220. Fingas CD, Bronk SF, Werneburg NW, Mott JL, Guicciardi ME, et al. 2011. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology 54:2076-88
221. Erkan M, Reiser-Erkan C, Michalski CW, Deucker S, Sauliunaite D, et al. 2009. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 11:497-508
222. Sirica AE, Campbell DJ, Dumur CI. 2011. Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma. Curr. Opin. Gastroenterol. 27:276-84
223. Al-Bahrani R, Nagamori S, Leng R, Petryk A, Sergi C. 2015. Differential expression of SonicHedgehog protein in human hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Pathol. Oncol. Res. 21:901-8
224. Yang L, Wang Y, Mao H, Fleig S, Omenetti A, et al. 2008. Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. J. Hepatol. 48:98-106
225. Theunissen JW, de Sauvage FJ. 2009. Paracrine Hedgehog signaling in cancer. Cancer Res. 69:6007-10
226. Kim Y, Kim MO, Shin JS, Park SH, Kim SB, et al. 2014. Hedgehog signaling between cancer cells and hepatic stellate cells in promoting cholangiocarcinoma. Ann. Surg. Oncol. 21:2684-98
227. Boulter L, Guest RV, Kendall TJ,Wilson DH,Wojtacha D, et al. 2015. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J. Clin. Investig. 125:1269-85
228. Jung KY,Cho SW, Kim YA, Kim D, Oh BC, et al. 2015. Cancers with higher density of tumor-associated macrophages were associated with poor survival rates. J. Pathol. Transl. Med. 49:318-24
229. Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, et al. 2010. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 101:1913-19
230. TechasenA,LoilomeW,Namwat N, Dokduang H, Jongthawin J, Yongvanit P. 2012. Cytokines released from activated human macrophages induce epithelial mesenchymal transition markers of cholangiocarcinoma cells. Asian Pac. J. Cancer Prev. 13(Suppl.):115-18
231. Techasen A,NamwatN,Loilome W, Bungkanjana P, KhuntikeoN, et al. 2012. Tumor necrosis factor-α (TNF-α) stimulates the epithelial-mesenchymal transition regulator Snail in cholangiocarcinoma. Med. Oncol. 29:3083-91
232. Xu LB, Liu C, GaoGQ, Yu XH, Zhang R, Wang J. 2010. Nerve growth factor-βexpression is associated with lymph node metastasis and nerve infiltration in human hilar cholangiocarcinoma. World J. Surg. 34:1039-45
233. Ogasawara S, Yano H, Higaki K, Takayama A, Akiba J, et al. 2001. Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines. Hepatol. Res. 20:97-113
234. YoshikawaD,Ojima H, IwasakiM,Hiraoka N, Kosuge T, et al. 2008. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br. J. Cancer 98:418-25
235. Shirabe K, Shimada M, Tsujita E, Aishima S, Maehara S, et al. 2004. Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis. Am. J. Surg. 187:538-42
236. Thelen A, Scholz A, Weichert W, Wiedenmann B, Neuhaus P, et al. 2010. Tumor-associated angiogenesis and lymphangiogenesis correlate with progression of intrahepatic cholangiocarcinoma. Am. J. Gastroenterol. 105:1123-32
237. Leek RD, Lewis CE,Whitehouse R, Greenall M, Clarke J, Harris AL. 1996. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56:4625-29
238. Lewis CE, Pollard JW. 2006. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66:605-12
239. Claperon A, Mergey M, Aoudjehane L, Ho-Bouldoires TH, Wendum D, et al. 2013. Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. Hepatology 58:2001-11
240. Fingas CD,Mertens JC, Razumilava N, Bronk SF, Sirica AE, Gores GJ. 2012. Targeting PDGFR-βin cholangiocarcinoma. Liver Int. 32:400-9
241. Wiedmann MW,Mossner J. 2010. Molecular targeted therapy of biliary tract cancer-results of the first clinical studies. Curr. Drug Targets 11:834-50
242. Riener MO, Fritzsche FR, Soll C, Pestalozzi BC, Probst-Hensch N, et al. 2010. Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. Histopathology 56:600-6
243. Sirica AE, Almenara JA, Li C. 2014. Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications. Exp. Mol. Pathol. 97:515-24
244. Baril P,Gangeswaran R, Mahon PC, Caulee K, KocherHM, et al. 2007. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the β4 integrin and the PI3k pathway. Oncogene 26:2082-94
245. Utispan K, Sonongbua J, Thuwajit P, Chau-In S, Pairojkul C, et al. 2012. Periostin activates integrin α5β1 through a PI3K/AKTdependent pathway in invasion of cholangiocarcinoma. Int. J. Oncol. 41:1110-18
246. Ruan K, Bao S, Ouyang G. 2009. The multifaceted role of periostin in tumorigenesis. Cell. Mol. Life Sci. 66:2219-30
247. Kawahara N, Ono M, Taguchi K, Okamoto M, Shimada M, et al. 1998. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. Hepatology 28:1512-17
248. Tang D, Nagano H, Yamamoto H, Wada H, Nakamura M, et al. 2006. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol. Rep. 15:525-32
249. Distler JH, Jungel A, Pileckyte M, Zwerina J, Michel BA, et al. 2007. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum. 56:4203-15
250. Sargiannidou I, Zhou J, Tuszynski GP. 2001. The role of thrombospondin-1 in tumor progression. Exp. Biol. Med. 226:726-33
251. Lai GH, Radaeva S, Nakamura T, Sirica AE. 2000. Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated "intestinaltype" biliary cancer chemically induced in rat liver. Hepatology 31:1257-65
252. Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, et al. 2011. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br. J. Cancer 105:131-38
253. Matsumoto K, Nakamura T. 2006. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int. J. Cancer 119:477-83
254. Ohira S, SasakiM,Harada K, Sato Y, Zen Y, et al. 2006. Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-αand stromal-derived factor-1 released in stroma. Am. J. Pathol. 168:1155-68
255. Leelawat K, Leelawat S, Narong S, Hongeng S. 2007. Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. World J. Gastroenterol. 13:1561-68
256. Zhao S, Wang J, Qin C. 2014. Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway. J. Exp. Clin. Cancer Res. 33:103
257. Liu H, Xue W, Ge G, Luo X, Li Y, et al. 2010. Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1αin MSCs. Biochem. Biophys. Res. Commun. 401:509-15
258. Penn MS. 2010. SDF-1:CXCR4 axis is fundamental for tissue preservation and repair. Am. J. Pathol. 177:2166-68
259. Teicher BA, Fricker SP. 2010. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer. Res. 16:2927-31
260. Okabe H, Beppu T, Ueda M, Hayashi H, Ishiko T, et al. 2012. Identification of CXCL5/ENA-78 as a factor involved in the interaction between cholangiocarcinoma cells and cancer-associated fibroblasts. Int. J. Cancer 131:2234-41
261. Huang L, Xu AM, Liu S, Liu W, Li TJ. 2014. Cancer-associated fibroblasts in digestive tumors. World J. Gastroenterol. 20:17804-18
262. Li H, Fan X, Houghton J. 2007. Tumor microenvironment: the role of the tumor stroma in cancer. J. Cell Biochem. 101:805-15
263. Silzle T, Randolph GJ, Kreutz M, Kunz-Schughart LA. 2004. The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int. J. Cancer 108:173-80
264. Korpos E, Wu C, Sorokin L. 2009. Multiple roles of the extracellular matrix in inflammation. Curr. Pharm. Des. 15:1349-57
265. Van Lint P, Libert C. 2007. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J. Leukoc. Biol. 82:1375-81